Login | Register

Lilly’s Solanezumab Slows Down Alzheimer’s Progression



Solanezumab, an experimental Eli Lilly medication for Alzheimer’s disease, slowed the rate of cognitive decline and memory loss by approximately 30% among patients in early stages of the disease. Eli Lilly says the results of its latest clinical trial provides initial evidence that solanezumab may have an impact on the course of the disease…

Leave a Reply

Your email address will not be published. Required fields are marked *